Skip to main content
Premium Trial:

Request an Annual Quote

DNA2.0 Wins NSF Funding

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Synthetic gene developer DNA 2.0 said today that it will use a grant from the National Science Foundation to continue to advance its synthetic biology technologies, with a specific focus on mammalian cells.

The firm plans to use the Small Business Innovation Research award to extend its gene optimization algorithms for protein expression, which is used in producing hosts for human therapeutics.

According to DNA2.0, this is a NSF Phase IIb grant for $300,000. For Phase II, the firm had received $800,000, bringing the total for this research to over $1 million.

The Menlo Park, Calif.-based company is continuing to develop technologies it made for use in unicellular systems, such as E. coli and yeast, for use with humans.

"By applying experimental design methods borrowed from other engineering disciplines, we can enable automated gene design that ensures consistent high-protein expression in your host of choice," DNA2.0 Director for Gene Design Mark Welch said in a statement.

"Mammalian cells are often critical for the production of fully-functional mammalian proteins, which account for the majority of high-value protein therapeutics and therapeutic targets. Poor expression yield is often a barrier to the study and production of such proteins," he added.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.